Heron Therapeutics (HRTX) to Release Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Stock Down 9.3 %

Shares of NASDAQ:HRTX opened at $2.24 on Tuesday. The firm has a market capitalization of $340.69 million, a PE ratio of -12.44 and a beta of 1.60. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The company has a 50-day moving average price of $1.70 and a two-hundred day moving average price of $1.71.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday. StockNews.com upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.